King Pharmaceuticals KG Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's deferred tax assets operating loss carryforwards subject to expiration.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's deferred tax assets operating loss carryforwards subject to expiration?
- King Pharmaceuticals (KG) reported deferred tax assets operating loss carryforwards subject to expiration of $387.59M in Q1 2026.